NEW YORK, August 24, 2026, 08:40 EDT
- SELLAS gained 15.37% on Friday and advanced another 1.62% ahead of Monday’s opening bell.
- The premarket share price was 1.1% lower than its 52-week peak.
- On Friday, cash accounted for just 4.4% of the $3.12 billion market value.
- The primary short-term catalyst continues to be the event-driven final analysis for REGAL.
SELLAS Life Sciences Group, Inc. NASDAQ:SLS shares built on Friday’s 15.37% surge in premarket trade Monday, rising a further 1.62% to $15.71 at 08:40 EDT. The stock was 1.1% shy of its 52-week peak at $15.88.
The underlying figure is more telling. On Friday, equity value reached $3.12 billion, surpassing June cash holdings by roughly $2.98 billion. This meant investors attributed 95.6% of the valuation to the drug pipeline and other non-cash assets.
The premium is narrowing as one key event approaches. SELLAS is now waiting for the event threshold that will trigger the final analysis in its Phase 3 REGAL trial. Friday’s surge was not matched by any fresh company announcement, indicating the move was mainly an adjustment of expectations.
| Trading point | Price | Change | Volume |
|---|---|---|---|
| August 17 close | $13.00 | +1.72% | 5.40 million |
| August 20 close | $13.40 | -3.25% | 7.73 million |
| August 21 close | $15.46 | +15.37% | 15.11 million |
| August 24 premarket, 08:40 EDT | $15.71 | +1.62% | Premarket |
The stock rose 18.9% between August 17 and Friday. Trading volume on Friday was nearly three times higher than on Monday. This pattern suggests increased event-driven positioning rather than a temporary price fluctuation.
REGAL is evaluating galinpepimut-S for acute myeloid leukemia patients in their second complete remission. The trial’s final analysis will be conducted after the 80th predetermined event. SELLAS reported that 78 events had happened as of May 11 and stated the study remains blinded to results.
| Program | Latest verified status | Next investor milestone | Timing |
|---|---|---|---|
| GPS / REGAL Phase 3 | As of May 11, 78 of 80 events; threshold said to be near on August 11 | Database lock, blinded assessment, unblinding and main results | Based on number of events |
| SLS009 frontline AML Phase 2 | 28 participants enrolled out of 80 planned | Headline data | Q4 2026 |
| SLS009 pancreatic cancer | Preclinical results announced | Meeting presentation and next development steps | Unspecified |
SELLAS Chief Executive Angelos Stergiou stated the company was “approaching the pre-specified 80th event.” He noted that a positive analysis might underpin a future U.S. biologics application. SELLAS will disclose when the threshold is met.
SLS009 provides an additional path to value, though supporting data are at an earlier stage. As of August 11, the frontline AML trial had enrolled 28 patients. Initial results are anticipated in the fourth quarter.
| Friday valuation summary | Value | Portion of market value |
|---|---|---|
| Stock market value | $3.120 billion | 100.0% |
| Cash holdings and equivalents, June 30 | $138.3 million | 4.4% |
| Estimated pipeline and additional value | $2.982 billion | 95.6% |
The balance sheet eases short-term financing strain, though dilution risk remains. The number of outstanding shares climbed to 201.9 million as of June 30, up from 153.1 million at the end of the year. Research expenses in the second quarter also rose 61.9% to $6.3 million.
| Analyst / firm | Recommendation | Target | Recent action |
|---|---|---|---|
| Maxim | Buy | $30 | Reaffirmed August 19 |
| James Molloy / Alliance Global | Buy | $35 | Increased from $25 on August 17 |
| Two-analyst aggregate | Buy | $32.50 average | 110.2% higher than Friday’s close |
Maxim described the latest Phase 3 cancer vaccine results as a “win for cancer vaccines.” James Molloy of Alliance Global stated that SLS009 seems to be leading among CDK9 candidates. Both analysts maintained Buy ratings, with targets reflecting anticipated clinical advancement.
Risks: REGAL represents a binary clinical catalyst, with progress determined by events. An unfavorable outcome could remove much of the pipeline premium. Key risks also include delays, regulatory issues, trial expenses, and additional share offerings.
The coming week’s focus shifts away from an updated price target. Market participants are expected to track the 80th-event announcement and any updates on when the database may be locked. In the meantime, the $2.98 billion premium continues to be a market projection under ongoing scrutiny.
Related articles: NASDAQ:SLS
